We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

MicroGem

MicroGEM is democratizing molecular biology by moving molecular techniques out of conventional, highly skilled labora... read more Featured Products: More products

Download Mobile App





World's First SARS-CoV-2 Saliva PCR System for POC Delivers Results in 30 Minutes

By LabMedica International staff writers
Posted on 18 Aug 2022
Print article
Image: Sal6830 detects SARS-CoV-2 at the point of care in under 30 minutes (Photo courtesy of MicroGEM)
Image: Sal6830 detects SARS-CoV-2 at the point of care in under 30 minutes (Photo courtesy of MicroGEM)

The world continues to see COVID-19 cases and related deaths, with new cases and hospitalizations driven by the Omicron BA.5 variant. In today's 'new normal', where activities are resuming among vaccinated and unvaccinated people, testing can help relieve the burden and anxiety about who is sick and infectious. Now, the first-of-their-kind PCR-based system and saliva test can enable fast, simple, on-the-spot detection of COVID-19 infection.

The MicroGEM Sal6830 Point of Care PCR System and SARS-CoV-2 Saliva Test from MicroGEM International (Charlottesville, VA, USA) give people timely answers about their health status, allowing them to quickly return to regular activities or immediately isolate and get care. The Sal6830 leverages MicroGEM's proprietary point of care technology, which combines enriched intact virus, thermophilic enzymatic RNA extraction, and microscale high-speed RT-PCR to capture whole virus to detect SARS-CoV-2 in under 30 minutes.

Sal6830's non-invasive saliva sampling, simple on-screen instructions, fast on-the-spot results, and portability provide an invaluable tool to quickly and accurately detect COVID-19 in settings ranging from healthcare centers, film production sets, and government and academic facilities, to mobile testing sites, retirement homes and long-term care communities. The Sal6830 SARS-CoV-2 Saliva Testing Kit's innovative cartridge design allows new targets to be added or replaced quickly, significantly reducing both assay and product development time.

The MicroGEM Sal6830 Point of Care PCR System and the MicroGEM Sal6830 SARS-CoV-2 Saliva Test recently received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). The company plans on seeking authorization to expand the test menu and ruggedize the system to address austere field conditions presented in military and disaster medicine use cases, and adapt the system for the precision medicine healthcare market with quantitative gene expression panels used as biomarkers.

"Sal6830 is transforming the 'new normal' of living and working with COVID-19 by providing an easy, convenient saliva test that eliminates the discomfort of nasal swabs," said Geoff Stein, Director of Channel Partner Sales for MicroGEM.

Related Links:
MicroGEM International 

Gold Supplier
SARS-CoV-2 Neutralization Antibody Test
UNICELL-2019-nCoV Neutralization Antibody Test
New
Automated Hematology Workstation
XN-3000
New
Silver Supplier
MDF-U731M-PE Biomedical -30°C Freezer
PHCbi MDF-U731M-PE
New
Anti-HIV 1/2 ELISA Test
HIV 1/2 Antibody (3rd) Test Kit (ELISA)

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Special blood test could determine if patient has early stage breast cancer and if the cancer is unlikely to return (Photo courtesy of USC)

Simple Blood Draw Could Revolutionize Early Breast Cancer Detection

Breast cancer is the most prevalent form of cancer in the world, affecting one in eight women over their lifetime. Since 1976 when the American Cancer Society endorsed mammography X-rays, the technique... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.